# Efficacy and Safety Study of TAS5315 Compared With Placebo in Participants With Rheumatoid Arthritis.

> **NCT03605251** · PHASE2 · COMPLETED · sponsor: **Taiho Pharmaceutical Co., Ltd.** · enrollment: 91 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** TAS5315 low dose
- **DRUG:** TAS5315 high dose
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03605251
- **Lead sponsor:** Taiho Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-30
- **Primary completion:** 2019-11-30
- **Final completion:** 2020-05-28
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2020-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03605251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03605251, "Efficacy and Safety Study of TAS5315 Compared With Placebo in Participants With Rheumatoid Arthritis.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03605251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*